Shots:
- ArsenalBio to receive $70M as up front and is eligible to receive additional payments associated with collaboration expansion, regulatory & commercial milestones along with royalties on sales of approved products
- ArsenalBio will be responsible for discovering and building preclinical candidates against multiple targets while BMS to get an option to obtain an exclusive WW license to develop & commercialize preclinical candidates
- The collaboration integrates ArsenalBio’s programmable cell therapy approach with BMS’ expertise in cell therapy and oncology drug development
Click here to read full press release/ article | Ref: Businesswire | Image: Linkedin
The post BMS Collaborates with ArsenalBio to Advance Next-Generation T cell Therapies for Solid Tumors first appeared on PharmaShots.
